Latest Breaking News On - Eyepoint pharmaceuticals nasdaq - Page 2 : comparemela.com

EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary.

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)

WATERTOWN - EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that.

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema